Floatz logo

Nicardipine

Hepato Cellular Carcinoma (HCC)

University Hospital, Basel, SwitzerlandSmall moleculePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Hepato Cellular Carcinoma (HCC) cohort.

Asset / SponsorPhaseRating
INDOMETACINUM
National Taiwan University Hospital
Phase 2CCC
TAURURSODIOL
Fudan University
Phase 2CCC
Anti-EGFR Antibody-drug Conjugate MRG003
Fudan University
Phase 2CCC
bc3402
Case Comprehensive Cancer Center
Phase 1/2CC
LIDOCAINE
Iuliu Hatieganu University of Medicine and Pharmacy
N/AD
FENTANYL
Iuliu Hatieganu University of Medicine and Pharmacy
N/AD

Same molecule, other indications

Nicardipine is also rated in:

malignant hypertensionDormant
BB
Indicative ·
69 / 100
View asset →
hypertensive disorderDormant
BB
Indicative ·
67 / 100
View asset →
ischemic strokeDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →